Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
KVUE.US
id: 844

Kenvue Inc. (KVUE) IPO Case

D. New Jersey
Court
1:23-cv-20998
Case number
03 May 2023
Class period Start
09 Oct 2023
Class period End
08 Dec 2023
Lead Plaintiff motion deadline
  • In September 2023, the FDA published a report questioning Kenvue's phenylephrine efficacy.
  • On this news, $KVUE declined by 4.5% and 8% since the IPO, damaging shareholders.
  • Investors suspect Kenvue's IPO contained inaccurate information about the effectiveness of phenylephrine.
On September 12, 2023, the FDA published a report stating that it was convening an advisory committee to discuss the adequacy of efficacy data available for Kenvue's (KVUE) orally-administered phenylephrine as a nasal decongestant and whether it and phenylephrine bitartrate should be reclassified as not Generally Recognized as Safe and Effective (GRASE) due to lack of efficacy.

On this news, $KVUE declined by 4.58%.

On November 12, 2021, Johnson & Johnson announced the creation of Kenvue as a wholly-owned consumer health subsidiary. On May 3, 2022, $JNJ and Kenvue jointly announced that the price of Kenvue’s IPO would be $22 per share.

Since the IPO, the $KVUE price has fallen by over 8% below its IPO price, damaging investors.

Considering all the information, investors have grounds to suspect that the Registration Statement for Kenvue's IPO contained inaccurate information, as it did not disclose potential challenges related to the effectiveness of phenylephrine, failed to address known concerns since 2007, omitted specific litigation risks tied to phenylephrine efficacy, and consequently, the defendants' public statements were materially false and misleading.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
09 October 2023
Filing date
09 October 2023
Lead Plaintiff Deadline
08 December 2023
Collecting participants…

Kenvue Inc.

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough...

    Ticker
    KVUE.US
    ISIN
    US49177J1025
    CIK
    1944048
    Sector
    Consumer Defensive
    Industry
    Household & Personal Products
    Country
    USA
    Address
    199 Grandview Road, Skillman, NJ, United States, 08558